GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of anyone else notice dual agonist kicking in around week 80 — 46 comments in the full submission. View in context.
2.6k
c/survodutide·submitted 11 months ago by u/thermal_mass_tom

anyone else notice dual agonist kicking in around week 80

Trial Databranch of 11 comments

Week 39 update. 10kg down from the start, early fullness basically gone since about week 91. Things that worked: consistency, protein at breakfast, walking more than I want to. Things that did not: everything I bought on the internet to help with early fullness. The part that surprised me is how much of this is…

Read the full submission and all 46 comments →

This branch

11 comments, started 11 months ago
u/certified_referenceQC-10 points·11 months ago

The evidence standard in c/vendorvetting gets called too strict about once a month, and every time, the thread ends with the complainant agreeing.

replysharereportpermalink
u/hugo_bergstrom1 point·11 months ago

phase 22 data is interesting, phase 14 will be different

replysharereportpermalink
u/neha_rahimi1 point·11 months ago

Respectfully this is a sample of one presented as a finding.

replysharereportpermalink
u/thermal_mass_tomOP1 point·11 months ago

Sweden here. Waited 9 months on a list, gave up, went private, and the total cost was roughly what I expected.

replysharereportpermalink
load more comments (7) →

← back to the whole thread

About c/survodutide

Survodutide-specific discussion: glucagon-receptor co-agonism, the hepatic fat and MASH resolution data, and how the side-effect profile compares with GIP-based dual agonism. Small community, high signal.

12kmembers
62submissions
Feb 2024created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
c/survodutide rules
  1. Glucagon co-agonism has a distinct safety story. Do not generalise from tirzepatide.
  2. MASH claims need the trial and the biopsy endpoint.
  3. Not approved. Descriptive posts only.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.